The healthcare system in the United States is in dire need of reform, and the culprit is the so-called 'Big Medicine' conglomerates. These entities, including pharmacy benefit managers (PBMs), insurance companies, and drug distributors, have been driving up healthcare costs and stifling competition, ultimately harming both patients and providers. The situation is akin to a financial crisis, where the common ownership of commercial and investment banks led to systemic risks. Similarly, the concentration of power in Big Medicine poses a catastrophic threat to the healthcare system.
One of the key issues is the vertical integration of these companies. For instance, the 'big three' PBMs, which control 80% of U.S. prescriptions, are also vertically integrated with major insurance conglomerates and pharmacies. This arrangement allows them to leverage their market power to drive up drug costs and push independent pharmacies out of business. The Federal Trade Commission's report in 2025 found that these PBMs paid their affiliated pharmacies up to 7,736% more than unaffiliated competitors, highlighting the extent of the problem.
The situation is further exacerbated by the drug wholesalers, who control 96% of U.S. drug distribution and are also vertically integrated with medical providers. This creates conflicts of interest, as seen in the case of Cencora, which agreed to pay $1 million to resolve allegations of paying kickbacks to healthcare providers. The result is that doctors' clinical judgment is often overridden by the profit margins of these companies, dictating which drugs patients receive.
The pharmaceutical industry is not entirely blameless, as Big Pharma abuses patents to keep drug costs high and block competition from more affordable generics. However, this doesn't absolve Big Medicine of its responsibilities. The situation is so dire that even incremental PBM reform efforts have stalled due to fierce opposition from industry groups, including Elon Musk, who tanked a bipartisan government funding bill that included PBM reforms.
The proposed Break Up Big Medicine Act, introduced by Sens. Elizabeth Warren and Josh Hawley, aims to address this issue by prohibiting insurers, PBMs, and wholesalers from owning or controlling healthcare providers. This bill would effectively break up all six of the Big Medicine companies, an effort to lower healthcare costs and promote competition. Public support for this kind of legislation is mounting, with business leaders like Mark Cuban endorsing the idea.
The healthcare system in the U.S. is at a critical juncture, and the Break Up Big Medicine Act could be a crucial step towards recovery. While it may not heal all the system's problems, it will begin the path to a more equitable and competitive healthcare system. Personally, I think that this is a necessary and long-overdue reform, and I hope that policymakers will take the necessary steps to implement it.
